MYOD1

Across TCGA pan-cancer cohorts, MYOD1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MYOD1 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MYOD1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MYOD1 expression acts as an unfavorable survival marker.

HNSC, LUAD, and SKCM are the cancer types where MYOD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.156	0.752	<.001	30	view →
LUAD	OS	Median	II,III,IV	0.163	0.750	.001	24	view →
SKCM	DFS	Median	All	0.290	0.740	<.001	21	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MYOD1–HNSC (OS)

Open the HNSC breakdown →